PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

a16z Bio

Menlo Park, CAA16Z-BIO
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

Andreessen Horowitz's dedicated bio fund focused on the convergence of biology and technology.

Classification
Sluga16z-bio
HQMenlo Park, CA
Stage FocusPrimarily Series A and B biotech/healthtech companies, wi…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

a16z Bio is the grown-up in the room for bio/healthtech investing. Unlike traditional biotech VCs who get spooked by tech, or tech VCs who don't understand FDA pathways, these folks actually get both sides. The partners have real operating experience and clinical backgrounds, which means they won't ask you to pivot to B2C when your B2B2C model hits regulatory hurdles. They're patient capital with 10+ year timelines, but expect you to show computational moats, not just wet lab progress. The a16z brand opens doors with pharma partnerships, but you'll need to prove platform scalability, not just single-asset potential.

KEY TAKEAWAYS
  • Best for: Platform companies bridging AI/tech with bio/healthcare
  • Known for: Patient capital with deep technical and clinical expertise
  • Watch out for: High bar for computational differentiation and scalability
Investment Thesis

a16z Bio invests in companies applying computation, engineering, and technology to transform biology and human health. They focus on breakthrough platforms that can create new categories of medicines, diagnostics, and health solutions.

Stage & Sector Focus

Primarily Series A and B biotech/healthtech companies, with some seed investments. Heavy focus on AI/ML platforms for drug discovery, synthetic biology, precision medicine, and digital health tools. Portfolio skews toward platform companies rather than single-asset biotechs.

Notable Portfolio
Devoted HealthFreenomeEikon TherapeuticsMindstrong HealthSigma TherapeuticsA-Alpha BioRecursion PharmaceuticalsRad AI
Key Partners
Vineeta Agarwala
General Partner

Former Google product manager and practicing physician (internal medicine). Known for bridging tech and healthcare, strong operator background. Founders appreciate her clinical perspective combined with product thinking.

Jorge Conde
General Partner

Former CEO of Knome and longtime biotech entrepreneur. Deep genomics and computational biology expertise. Respected for technical depth and ability to spot platform opportunities early.

Julie Yoo
General Partner

Co-founder of Kyruus and Heal, serial healthcare entrepreneur. Strong on go-to-market strategy and healthcare system adoption. Known as a hands-on partner who helps with business model design.

Have a specific question about a16z Bio?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1